Open Nav

Zenith Epigenetics Ltd.

  • Sanjay Lakhotia, Zenith Epigenetics Ltd.

Update on clinical and development programs for BET inhibitors.

  • Date:Wednesday, October 17
  • Time:3:45 PM - 4:00 PM
  • Room:Elizabethan B
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Zenith Epigenetics Ltd. is a clinical stage biotechnology company developing best in class bromodomain (BET) inhibitors for the treatment of cancer and other disorders with significant unmet medical need. Our cutting edge epigenetic platform of innovative biology and chemistry has generated differentiated, potent and selective BET inhibitors. Our goal is to be a leading epigenetic company translating bromodomain biology into impactful therapies. Our lead product, a pan selective BET inhibitor, is in clinical development for treatment of solid tumors, including prostate cancer. Our strong management team and organization allow us to efficiently and rapidly explore and progress molecules from discovery to clinical development. Our research team, based in Calgary, Alberta, is well-positioned to take advantage of its broad and longstanding experience in epigenetics to become a leader in the discovery of selective BET inhibitors in both oncology and other indications.
  • Company
  • Company HQ City:Calgary
  • Company HQ Country:Canada
  • Company HQ State:Alberta
  • CEO/Top Company Official:Donald McCaffrey
  • Year Founded:2013
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development :ZEN 3694
  • Development Phase of Primary Product:Phase II
  • Additional Information/Comments:Please cc Sarah Zapotichny on all communications
  • Total Amount Raised to Date, In All Rounds:44
Sanjay Lakhotia
Zenith Epigenetics Ltd.